1228675-25-9

Basic information

• Product Name: 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate
• Synonyms: 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate
• CAS NO: 1228675-25-9
• Molecular Formula: C₁₇H₂₂N₂O₅
• Molecular Weight: 334.38
• Mol File: 1228675-25-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate(1228675-25-9)
• EPA Substance Registry System: 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate(1228675-25-9)

Safety Data

• Hazardous Substances Data: 1228675-25-9(Hazardous Substances Data)

Usage

General Description

4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate is a chemical compound with the molecular formula C19H23NO6. It is a piperazine derivative, containing a benzyl and tert-butyl group, as well as two oxo and carboxylate functional groups. 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate is commonly used in organic synthesis and pharmaceutical research, and its derivatives have been studied for their potential therapeutic applications, including as antipsychotic agents. The structure of 4-Benzyl 1-Tert-Butyl 2-Oxopiperazine-1,4-Dicarboxylate makes it a promising candidate for further pharmacological development, as it exhibits a diverse range of potential biological activities.

Upstream product

• 501-53-1 benzyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 78818-15-2 4-benzyloxycarbonylpiperazin-2-one 

Downstream Products

• 1228675-26-0 4-benzyl 1-tert-butyl 2-hydroxypiperazine-1,4-dicarboxylate 
• 1589534-93-9 benzyl (3S)-4-(4-(methylcarbamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1589534-88-2 benzyl (3S)-4-phenyl-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1589535-34-1 benzyl 3-(1-propyn-1-yl)-4-(5-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-1,3-thiazol-2-yl)-1-piperazinecarboxylate 
• 1589535-33-0 benzyl 4-(5-acetyl-1,3-thiazol-2-yl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1589535-32-9 benzyl 4-(5-(methoxy(methyl)carbamoyl)-1,3-thiazol-2-yl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1589535-03-4 benzyl 4-(4-(methylsulfonyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1589534-98-4 benzyl (3S)-4-(4-(phenylsulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572928-06-3 benzyl (3S)-4-(4-((cyclopropylmethyl)-sulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572928-05-2 benzyl (3S)-3-(1-propyn-1-yl)-4-(4-(S-(trifluoromethyl)sulfonimidoyl)phenyl)-1-piperazinecarboxylate 
• 1572928-78-9 benzyl (3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-methylethyl)phenyl)-1-piperazinecarboxylate 
• 1572928-66-5 benzyl (3S)-4-(5-(1-hydroxy-1-methylethyl)-1,3-thiazol-2-yl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572928-65-4 benzyl (3S)-4-(5-acetyl-1,3-thiazol-2-yl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572928-63-2 benzyl (3S)-4-(5-(methoxy(methyl)carbamoyl)-1,3-thiazol-2-yl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 

Relevant articles and documents

Novel RET inhibitors. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitrid

Small molecule disruptors of the Glucokinase-Glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles

In the previous report, we described the discovery and optimization of novel small molecule disruptors of the GK-GKRP interaction culminating in the identification of 1 (AMG-1694). Although this analogue possessed excellent in vitro potency and was a useful tool compound in initial proof-of-concept experiments, high metabolic turnover limited its advancement. Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor (27, AMG-3969). When administered to db/db mice, this compound demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent reductions in fed blood glucose levels.

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N′-arylpiperazine series

We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small molecule to its endogenous inhibitor, glucokinase regulatory protein (GKRP) these initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3- pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3, 3-hexafluoro-2-propanol (1, AMG-3969), a compound that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals. Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series. Guided by the X-ray cocrystal structure of compound 1 bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region. Among them, sulfoximine and pyridinyl derivatives 24 and 29 possessed excellent potency as well as favorable PK properties. When dosed orally in db/db mice, both compounds significantly lowered fed blood glucose levels (up to 58%).